image credit- shutterstock
China's XtalPi Holdings, an AI and robotics-driven drug and materials discovery company, has debuted Kodexia™, the industry's first closed-loop small interfering RNA (siRNA) discovery platform combining generative AI, first-principles-driven biological modeling, and automated experimentation.
Validating the rapid execution capabilities of this new infrastructure, the company simultaneously announced the advancement of six proprietary therapeutic programs, marking the successful expansion of XtalPi's technology into nucleic acid therapeutics.
Kodexia™ also globally co-optimises dual-target siRNAs as single molecules, creating a strategy for disease biology that may not be adequately addressed through single-target intervention.
The platform's lead programme in immunoglobulin A (IgA) nephropathy serves as an early empirical validation of this unified architecture. programme is on track for preclinical candidate selection within a nine-month project timeline, significantly accelerating the industry norm of 12 to 18 months.
Kodexia™ currently drives six proprietary programmes across metabolic, renal, respiratory, and central nervous system diseases, with more than half having already completed in vivo efficacy evaluations.
